Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn’t stop at U.S. Food and Drug Administration (FDA) approval. After approval, scientists and physicians continue to generate information on a new medicine or vaccine, as we’re seeing with COVID-19 vaccines today. This is done both for approved indications and to develop the medicine potentially for new, supplemental indications treating important unmet medical needs.
